Title of article :
Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study
Author/Authors :
Michael A. Gatzoulis، نويسنده , , Maurice Beghetti، نويسنده , , Nazzareno Galiè، نويسنده , , John Granton، نويسنده , , Rolf M.F. Berger، نويسنده , , Andrea Lauer، نويسنده , , Eleonora Chiossi، نويسنده , , Michael Landzberg and on behalf of the BREATHE-5 Investigators، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2008
Pages :
6
From page :
27
To page :
32
Abstract :
Background Bosentan, an oral endothelin ETA/ETB receptor antagonist, improves hemodynamics and exercise capacity in patients with Eisenmenger syndrome but longer-term effects are unknown. This study investigated the efficacy and safety of bosentan up to 40 weeks in these patients. Methods Following the 16-week, double blind, placebo-controlled BREATHE-5 study of bosentan in patients with Eisenmenger syndrome, an open-label extension (OLE) was performed. Patients who completed BREATHE-5 received bosentan for an additional 24 weeks (62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.) and were analyzed in two groups; ex-placebo and ex-bosentan, according to BREATHE-5 treatment. Results Thirty-seven patients with Eisenmenger syndrome who participated in BREATHE-5 were included in the OLE. At week 24, the 6-minute walk distance (mean ± SE) increased from OLE baseline for the ex-placebo (+ 33.2 ± 23.9 m) and ex-bosentan group (+ 6.7 ± 10.0 m). The overall improvement from baseline of BREATHE-5 was + 61.3 ± 8.1 m (95% confidence interval: [44.7, 78.0]) for the ex-bosentan group. WHO functional class was improved in both groups. Bosentan did not reduce systemic arterial blood oxygen saturation; safety profile was comparable to previous trials. Conclusions In conclusion, these longer follow-up data support the efficacy and safety profile reported in the preceding BREATHE-5 study of bosentan treatment of Eisenmenger syndrome, challenging the notion that pulmonary vascular disease and severe functional impairment in these patients are not amenable to therapy.
Keywords :
Bosentan , Endothelin receptor antagonism , pulmonary arterial hypertension , Eisenmenger syndrome
Journal title :
International Journal of Cardiology
Serial Year :
2008
Journal title :
International Journal of Cardiology
Record number :
815993
Link To Document :
بازگشت